Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2731
Source ID: NCT01043029
Associated Drug: Aleglitazar
Title: A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG: aleglitazar|DRUG: pioglitazone
Outcome Measures: Primary: Renal function: estimated glomerular filtration rate, Week 60 | Secondary: Safety, Tolerability: Adverse events (AEs), laboratory parameters, AEs: Throughout study, laboratory assessments: Week 2, 4, 8, 12, 16, 20, 26, 39, 52, 56, 60|Renal function: estimated glomerular filtration rate, Week 52|Effect on blood hemoglobin, Week 52
Sponsor/Collaborators: Sponsor: Hoffmann-La Roche
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 302
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2010-05
Completion Date: 2012-07
Results First Posted:
Last Update Posted: 2016-11-02
Locations: Camperdown, New South Wales, 2050, Australia|St. Leonards, New South Wales, 2065, Australia|Brisbane, Queensland, 4075, Australia|Elizabeth Vale, South Australia, 5112, Australia|Richmond, South Australia, 3121, Australia|Launceston, Tasmania, 7001, Australia|Melbourne, Victoria, 3004, Australia|Fortaleza, CE, 60135-170, Brazil|Porto Alegre, RS, 90035-170, Brazil|Sao Paulo, SP, 01221-020, Brazil|Sao Paulo, SP, 04022-001, Brazil|Sao Paulo, SP, 04231-030, Brazil|Barranquilla, Colombia|Bogota, Colombia|Bucaramanga, Colombia|Medellin-Antioquia, Colombia|San Salvador, El Salvador|Aschaffenburg, 63739, Germany|Berlin, 10115, Germany|Damme, 49401, Germany|Dresden, 01307, Germany|Essen, 45359, Germany|Falkensee, 14612, Germany|Mainz, 55116, Germany|Münster, 48145, Germany|Neuwied, 56564, Germany|Reichenbach, 08468, Germany|Rostock, 18059, Germany|Sulzbach-Rosenberg, 92237, Germany|Würzburg, 97072, Germany|Hong Kong, Hong Kong|Tuen Mun, 852, Hong Kong|Baja, 6500, Hungary|Budapest, 1036, Hungary|Budapest, 1045, Hungary|Budapest, 1135, Hungary|Debrecen, 4032, Hungary|Kecskemet, 6001, Hungary|Miskolc, 3526, Hungary|Satoraljaujhely, 3980, Hungary|Szeged, 6720, Hungary|Szekszard, 7100, Hungary|Genova, Liguria, 16132, Italy|Bergamo, Lombardia, 20128, Italy|Cusano Milanino, Lombardia, 20095, Italy|Milano, Lombardia, 20132, Italy|Pavia, Lombardia, 27100, Italy|Aguascaliente, 20230, Mexico|Chihuahua, 31238, Mexico|Cuernavaca, 62250, Mexico|Durango, 34080, Mexico|Guadalajara, 44600, Mexico|Guadalajara, 44650, Mexico|Pachuca, 42060, Mexico|Pachuca, 42090, Mexico|Arequipa, Cercado, Peru|Lima, 11, Peru|Lima, LIMA 29, Peru|Bucharest, 020475, Romania|Cluj-napoca, 400006, Romania|Iasi, 700 503, Romania|Ploiesti, 100163, Romania|Sibiu, 550245, Romania|Targu Mures, 540142, Romania|Chelyabinsk, 454047, Russian Federation|Moscow, 119121, Russian Federation|Moscow, 121069, Russian Federation|Moscow, 125101, Russian Federation|Moscow, 127299, Russian Federation|Moscow, 129110, Russian Federation|Saint-Petersburg, 194156, Russian Federation|Saratov, 140018, Russian Federation|St Petersburg, 195067, Russian Federation|St Petersburg, 195257, Russian Federation|St Petersburg, 197089, Russian Federation|Yaroslavl, 150062, Russian Federation|Bratislava, 821 02, Slovakia|Dolny Kubin, 026 01, Slovakia|Levice, 034 01, Slovakia|Lucenec, 984 01, Slovakia
URL: https://clinicaltrials.gov/show/NCT01043029

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D336 Pioglitazone small molecule DB01132 Details